UK's Bicycle Therapeutics Q2 net loss narrows on reduced clinical program expenses

Bicycle Therapeutics

30/07/2026 12:38

Overview
UK oncology drug developer's Q2 net loss narrowed from prior year
Collaboration revenue for Q2 declined sharply year-over-year
Lower operating expenses driven by reduced clinical program and personnel costs after workforce reduction

Outlook
Company expects cash runway to extend into 2030
Bicycle Therapeutics remains on track to begin BT1702 Phase 1 trial in 2027
Company is actively enrolling patients in Phase 2 trial for nuzefatide in recurrent pancreatic cancer

Result Drivers
LOWER CLINICAL AND PERSONNEL COSTS - Co said reduced clinical program expenses and workforce reduction drove lower R&D and G&A expenses
OPERATIONAL SPENDING - Decrease in cash and cash equivalents was primarily due to cash used in operations, including clinical program activities

Company press release: ID:nBw5LzY5Ya

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$50.33 mln
 
Q2 Loss Per Basic Share
 
$0.72
 
Q2 Operating Expenses
 
$55.19 mln
 
Q2 Operating Incom
 
-$54.56 mln
 
Q2 Pretax Loss
 
$50.24 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $12.00, about 210.9% above its July 29 closing price of $3.86

Reuters Recommended Reads
July 28 - US FDA staff cast doubt on Replimune cancer drug's benefit; shares slide
July 29 - Ionis Q2 adjusted operating loss narrows
July 29 - Dyne Therapeutics reports larger-than-expected Q2 net loss per share

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)